07.01.08
The Withania somnifera extract (WSE) in Sensoril significantly reduced stress-related parameters and cardiovascular risk, according to a human clinical study recently published in the Journal of the American Nutraceutical Association (JANA). Sensoril is a patented, GRAS (Generally Recognized as Safe) ingredient for food and supplements supplied by Natreon.
Utilizing a randomized, double-blind, placebo-controlled study design, researchers investigated the impact of the WSE—also known as ashwagandha—contained in Sensoril on experiential and biochemical indicators of stress and anxiety, as well as cardiovascular risk, in 98 chronically stressed adults. Participants in the study were identified as “stressed” by clinical assessments on a modified Hamilton anxiety (mHAM-A) scale. The scale rated common symptoms of anxiety, including irritability, sleeplessness and body aches, among others. Participants in all WSE treatment groups experienced significantly improved well-being, with their mHAM-A score decreasing by nearly 40% by day 30 and 62% by day 60. In contrast, the placebo group showed no significant change in the objective and subjective measures of stress.
Stress hormones in the body also decreased substantially after 2 months. Serum cortisol decreased by almost 15%, as did other stress indicators. Interestingly, the anti-aging, anti-stress hormone DHEA increased significantly (13.2%) among those taking Sensoril.
The study also showed that Sensoril reduced levels of the C-reactive protein, which is a marker of systemic inflammation and a recognized indicator of cardiovascular risk.
For further information: 212-693-2150.
Utilizing a randomized, double-blind, placebo-controlled study design, researchers investigated the impact of the WSE—also known as ashwagandha—contained in Sensoril on experiential and biochemical indicators of stress and anxiety, as well as cardiovascular risk, in 98 chronically stressed adults. Participants in the study were identified as “stressed” by clinical assessments on a modified Hamilton anxiety (mHAM-A) scale. The scale rated common symptoms of anxiety, including irritability, sleeplessness and body aches, among others. Participants in all WSE treatment groups experienced significantly improved well-being, with their mHAM-A score decreasing by nearly 40% by day 30 and 62% by day 60. In contrast, the placebo group showed no significant change in the objective and subjective measures of stress.
Stress hormones in the body also decreased substantially after 2 months. Serum cortisol decreased by almost 15%, as did other stress indicators. Interestingly, the anti-aging, anti-stress hormone DHEA increased significantly (13.2%) among those taking Sensoril.
The study also showed that Sensoril reduced levels of the C-reactive protein, which is a marker of systemic inflammation and a recognized indicator of cardiovascular risk.
For further information: 212-693-2150.
